Cargando…
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as v...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288953/ https://www.ncbi.nlm.nih.gov/pubmed/30537942 http://dx.doi.org/10.1186/s12886-018-0978-9 |
_version_ | 1783379894120480768 |
---|---|
author | Merz, Patrick R. Röckel, Nina Ballikaya, Seda Auffarth, Gerd U. Schmack, Ingo |
author_facet | Merz, Patrick R. Röckel, Nina Ballikaya, Seda Auffarth, Gerd U. Schmack, Ingo |
author_sort | Merz, Patrick R. |
collection | PubMed |
description | BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium. METHODS: Human donor corneas, not suitable for corneal transplantation, were organ-cultured in the presence of either ranibizumab (Lucentis®) or bevacizumab (Avastin®) at different concentrations (group 1: 250 μg / ml, group 2: 25 μg / ml, group 3: 2.5 μg / ml) for a period of up to 4 weeks. Microscopic imaging for endothelial cell counting, detection of morphologic alterations of the endothelium, and molecular biology testing (Enzyme-linked Immunosorbent Assay [ELISA]) for metabolic changes was performed. RESULTS: Background-corrected results showed neither a significant lactate dehydrogenase (LDH) change with increasing culturing time nor a significant difference between ranibizumab (Lucentis®) and bevacizumab (Avastin®) treatment. The endothelial cell density revealed also no statistically significant difference between the two treatment groups with ranibizumab (Lucentis®) and bevacizumab (Avastin®) at all concentrations tested in this study. CONCLUSIONS: In this study, the anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®) demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4 weeks. However, based on the study design (in-vitro) and the limited follow-up period, no conclusions on potential long-term effects can be drawn. |
format | Online Article Text |
id | pubmed-6288953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62889532018-12-14 Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells Merz, Patrick R. Röckel, Nina Ballikaya, Seda Auffarth, Gerd U. Schmack, Ingo BMC Ophthalmol Research Article BACKGROUND: Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium. METHODS: Human donor corneas, not suitable for corneal transplantation, were organ-cultured in the presence of either ranibizumab (Lucentis®) or bevacizumab (Avastin®) at different concentrations (group 1: 250 μg / ml, group 2: 25 μg / ml, group 3: 2.5 μg / ml) for a period of up to 4 weeks. Microscopic imaging for endothelial cell counting, detection of morphologic alterations of the endothelium, and molecular biology testing (Enzyme-linked Immunosorbent Assay [ELISA]) for metabolic changes was performed. RESULTS: Background-corrected results showed neither a significant lactate dehydrogenase (LDH) change with increasing culturing time nor a significant difference between ranibizumab (Lucentis®) and bevacizumab (Avastin®) treatment. The endothelial cell density revealed also no statistically significant difference between the two treatment groups with ranibizumab (Lucentis®) and bevacizumab (Avastin®) at all concentrations tested in this study. CONCLUSIONS: In this study, the anti-angiogenic agents ranibizumab (Lucentis®) and bevacizumab (Avastin®) demonstrated no cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4 weeks. However, based on the study design (in-vitro) and the limited follow-up period, no conclusions on potential long-term effects can be drawn. BioMed Central 2018-12-11 /pmc/articles/PMC6288953/ /pubmed/30537942 http://dx.doi.org/10.1186/s12886-018-0978-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Merz, Patrick R. Röckel, Nina Ballikaya, Seda Auffarth, Gerd U. Schmack, Ingo Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
title | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
title_full | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
title_fullStr | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
title_full_unstemmed | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
title_short | Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells |
title_sort | effects of ranibizumab (lucentis®) and bevacizumab (avastin®) on human corneal endothelial cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288953/ https://www.ncbi.nlm.nih.gov/pubmed/30537942 http://dx.doi.org/10.1186/s12886-018-0978-9 |
work_keys_str_mv | AT merzpatrickr effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT rockelnina effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT ballikayaseda effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT auffarthgerdu effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells AT schmackingo effectsofranibizumablucentisandbevacizumabavastinonhumancornealendothelialcells |